tbuckley/cabot-search huggingface dataset:
THU0123 FEMALES UNDERGO MORE TREATMENT CHANGES COMPARED TO MALES: ANALYSIS OF GENDER DIFFERENCES IN RHEUMATOID ARTHRITIS PATIENTS
Authors: ASTORRI DAVIDE, Francesca Ometto, Lara Friso, Francesco Sartor, Bernd Raffeiner, Costantino Botsios, Leonardo Punzi, Andrea Doria
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Gender differences may contribute to treatment tailoring in rheumatoid arthritis (RA) patients. Observational data shows a trend toward worse disease activity and worse response to treatment in females. Only few data are available specifically focused on differences in drug use according to gender. <h3>Objectives</h3> To evaluate gender differences in treatment approaches in RA patients treated with bDMARDs (biological DMARDs) <h3>Methods</h3> We included RA patients aged ≥18 years, with disease duration ≥1 years, with a stable bDMARD treatment (≥12 months) in a monocentric cohort in the North-East of Italy. Social, demographic, and clinical features in addition to treatments were considered. To assess variables independently associated with gender, all variables achieving a p&lt;0.20 in univariate analysis were included in a multivariate regression model. <h3>Results</h3> Among 721 RA patients, 514 patients were eligible for the analysis and 407 were females. Compared with males, females had a lower BMI, a higher DAS28, a higher number of conventional synthetic DMARDs (csDMARDs) used before the start of bDMARDs, a higher number of bDMARDs with different mechanism of action (MoA), a larger use of prednisone and a lower rate of combination with MTX (Table 1). After adjustment for confounding factors, females had an increased probability of taking ≥ 2 DMARDs before bDMARDs (OR 2.21, 95% CI 1.25-3.93, p=0.007) and a lower BMI (per 5-unit increase, OR 0.70, 95% CI 0.56-0.87, p=0.001) compared to males (Figure 1). <h3>Conclusion</h3> In a cohort of Italian RA patients, females were treated with a higher number of csDMARDs before starting a bDMARD compared to males and a trend toward the use of more bDMARDs with different MoA. Further insight is needed regarding possible differences in the accessibility to bDMARD treatment and reasons for unsatisfactory treatment control in females. <h3>Disclosure of Interests</h3> None declared
PB1769 INTERLEUKIN‐10 (1082G/A) GENE POLYMORPHISM IS ASSOCIATED WITH RISK OF ACUTE MYELOID LEUKEMIA IN SUDANESE POPULATION
Authors: I. Osman
Journal: HemaSphere (2019)

Background: Acute myeloid leukemia (AML) is a cytogenetically and molecularly heterogeneous diseases, and description of transforming genetic events is becoming increasingly significant. Interleukins (ILs) are a diverse set of small cell signaling protein molecules. Single nucleotide polymorphisms (SNPs) of ILs alter their function, increasing predisposition to different illnesses. Aims: We investigated the association between a single nucleotide polymorphism (SNP) in IL‐10 ‐1082G/A (rs1800896) in Sudanese acute myeloid leukemia patients Methods: A total of 30 patients with Acute Myeloid Leukemia and 30 control subjects were enrolled in this study. Blood samples were collected from all participants in EDTA containing tubes. Genomic DNA was extracted from all blood samples using salting out method. The genotypic variants of IL‐10(‐1082G/A) polymorphism were detected by allele specific‐PCR. Results: We found that (36.7%) of patients have homogenous GG genotype, (43.3%) have heterogeneous GA genotype and (20.0%) have AA genotype. GA genotype was significantly higher risk of AML compared with the homozygous, there is no association between IL‐10(‐1082G/A) polymorphism and AML sub‐type, gender, age group, mean of hematological parameter (TWBCs, Blast%, Hb and platelet count). Summary/Conclusion: In summary we conclude that GA genotype of IL‐10 ‐1082G/A (rs1800896) polymorphism is a risk factor for AML and G allele is insignificantly higher than A allele in AML patient. No association between IL‐10(‐1082G/A) polymorphism and AML sub‐type, gender, age group, mean of hematological parameter (TWBCs, Blast%, Hb and platelet count).
PF193 NO BLASTS AT DAY 8 IS BETTER THAN MORE IN CORTICO‐SENSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OF CHILDREN
Authors: I. Frikha, I. Turki, M. Medhaffer, S. Hdijji, I. Ben Amor, M. Charfi, O. Kassar, M. Ghorbel, F. Kallel, M. Elloumi
Journal: HemaSphere (2019)

Background: Acute lymphoblastic leukemia (ALL) had a good prognostic in children and young adults. However, some parameters were predictive of a worse outcome, particularly the poor response to prephase. Aims: We analysed in this study the impact of persistent blasts at day 8 of pre‐phase in cortico‐sensitives patients with ALL. Methods: Between january 2000 and December 2015, we retrospectively analysed the data of 264 children and young adults treated according the EORTC 58951 protocol. Cortico‐sensitivity (Cs) was considered if peripheral blast count is less than 1000/mm 3 at day 8 of pre‐phase. The group of cortico‐sensitives ALL was subdivided on two subgroups : the first with no blasts at day 8 (Cs = 0) and the second with more (Csǂ0). We analysed the impact of cortico‐sensitivity on complete remission (CR), relapse and survival (overall survival (OS), event free survival (EFS) and disease free survival (DFS)). Results: One hundred ninety two children and 72 young adults were treated according to the EORTC 58951 protocol. Median age was 10 years (1 to 30 years). Sex ratio was 1,5. B and T phenotype were observed in respectively 64 and 36% of cases. The ALL were stratified in low risk (11 patients), average risk (182 patients), and high risk (71 patients). Two hundred and nine patients (79%) were cortico‐sensitive, among them 150 patients (72%) had no blast at day 8 of pre‐phase. The therapeutics results in our study and into the two groups of cortico‐sensitivity were shown in this table : Summary/Conclusion: Cortico‐sensitivity is one of several parameters that predict good outcome in ALL. Moreover, our study showed that no blasts in peripheral blood smears at day 8of prephase can be considered a good first marker of early blastic clearance and good outcome. In fact, this parameter does not discussed previously in the literature. image
Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial
Authors: Hideki Ueno, Megumi Ishiguro, Eiji Nakatani, Toshiaki Ishikawa, Hiroyuki Uetake, Chu Matsuda, Yoshihiko Nakamoto, Masanori Kotake, Kiyotaka Kurachi, Tomohisa Egawa, Keigo Yasumasa, Kohei Murata, Osamu Ikawa, Seiichi Shinji, Kenta Murotani, Shigeyuki Matsui, Satoshi Teramukai, Naohiro Tomita, Kenichi Sugihara
Journal: Journal of Clinical Oncology (2019)

The International Union Against Cancer highlighted tumor budding as a tumor-related prognostic factor. International assessment criteria for tumor budding were recently defined by the 2016 International Tumor Budding Consensus Conference (ITBCC2016). This study aimed to clarify the prognostic and predictive values of tumor budding in a randomized controlled trial evaluating the superiority of adjuvant chemotherapy with oral tegafur-uracil over surgery alone for stage II colon cancer (SACURA trial; ClinicalTrials.gov identifier: NCT00392899).
Abstract 18600: Very Long-term Clinical Outcome After Sirolimus-eluting Stent Implantation
Authors: Shoichi Kuramitsu, Hiroaki Matsuda, Hiroyuki Jinnouchi, Takashi Hiromasa, Takenori Domei, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando
Journal: Circulation (2015)

Background: Late adverse events such as stent thrombosis (ST) or late target-lesion revascularization (TLR) after sirolimus-eluting stents (SES) implantation remain an important concern. However, there is little data regarding clinical outcome beyond 5 years after SES implantation. We sought to assess very long-term clinical outcome after SES implantation. Methods: Between April 2004 and December 2006, a total of 686 patients with 894 lesions underwent percutaneous coronary intervention only with SES. We assessed the major adverse cardiac events (MACE), defined as a composite of cardiac death, TLR, definite ST. Results: At 10 years, cumulative incidence of MACE and cardiac death were 50.8% and 8.2%, respectively. Cumulative incidence of TLR within 1 year was 12.6%. However, late TLR beyond 1 year continued to occur without attenuation up to 10 years (2.3%/year) (5 years, 22.8%; 10 years, 33.3%). Cumulative incidence of definite ST was low (30 days, 0.3%; 1 year, 0.9%; 5 years, 1.8%; and 10 years, 3.3%), whereas definite ST also continued to occur without attenuation (0.27%/year). The predictors of MACE were hemodialysis (hazard ratio [HR] 2.87, 95% confidence intervals [CI]:1.76-4.53, p &lt;0.001) and age ≥75 years (HR 1.72, 95% CI: 1.31-2.26, p &lt;0.001). Conclusions: Late catch-up phenomenon regarding ST and TLR continued up to 10 years without attenuation. Careful clinical follow-up is required in patients treated with SES beyond 5 years.
FRI0275 HIGH ANGIOPOIETIN-2 LEVELS ASSOCIATE WITH ARTERIAL INFLAMMATION AND LONG-TERM GLUCOCORTICOID REQUIREMENT IN POLYMYALGIA RHEUMATICA
Authors: Yannick van Sleen, Annemieke Boots, Wayel Abdulahad, Johan Bijzet, Maria Sandovici, Kornelis van der Geest, Elisabeth Brouwer
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Polymyalgia rheumatica (PMR) frequently co-occurs with giant cell arteritis (GCA). So far, a simple biomarker for detecting concomitant arterial inflammation in PMR patients is lacking. Furthermore, biomarkers predicting disease course in PMR are awaited. <h3>Objectives:</h3> We here investigated the diagnostic and prognostic value of acute-phase markers (ESR, CRP, IL-6, serum amyloid A) and angiogenesis markers (VEGF, soluble Tie2, angiopoietin-1, angiopoietin-2) in isolated PMR and PMR/GCA overlap patients. <h3>Methods:</h3> We prospectively included 39 treatment-naive PMR patients, of which 10 patients also showed evidence of large vessel GCA on FDG-PET/CT. Age-matched healthy controls (N=32) and infection controls (N=13) were included for comparison. Serum marker levels were measured by ELISA or Luminex. ROC and Kaplan Meier analyses were used to asses diagnostic and prognostic accuracy, respectively. <h3>Results:</h3> All acute-phase and angiogenesis markers, except angiopoietin-1, were higher in isolated PMR patients compared to HCs. Angiopoietin-2, ESR and soluble Tie-2 were significantly higher in patients with PMR/GCA overlap compared to isolated PMR patients. Angiopoeietin-2, but not soluble Tie2, outperformed ESR and CRP in discriminating patients with and without overlapping GCA (AUC 0.90). Moreover, high angiopoietin-2 levels were associated with long-term glucocorticoid requirement. <h3>Conclusion:</h3> Assessment of angiopoietin-2 at baseline may assist diagnosis of concomitant vasculitis in PMR. Moreover, high levels of angiopoietin-2 were associated with a unfavorable disease course in isolated PMR patients. These findings imply that angiopoietin-2 could be an interesting diagnostic and prognostic biomarker in PMR. <h3>Disclosure of Interests:</h3> Yannick van Sleen: None declared, Annemieke Boots Grant/research support from: grant from MSD in 2010-2015, Consultant for: I was a consultant for Grunenthal Germany 2016-2017, Employee of: I was an employee of Organon, Shering-Plough and MSD from 1991-2011, Wayel Abdulahad: None declared, Johan Bijzet: None declared, Maria Sandovici: None declared, Kornelis van der Geest: None declared, Elisabeth Brouwer Speakers bureau: Dr. Brouwer as an employee of the UMCG received speaker fees and consulting fees from Roche which were paid to the UMCG
Angiography-Derived Fractional Flow Reserve Versus Invasive Nonhyperemic Pressure Ratios
Authors: Nils P. Johnson, Mitsuaki Matsumura, Stephan Achenbach, Thomas Engstrom, Abid Assali, Allen Jeremias, Stephane Fournier, Bernard De Bruyne, Martin B. Leon, William F. Fearon
Journal: Journal of the American College of Cardiology (2019)
PS1595 PREVENTING ALLOIMMUNIZATION OF RECIPIENTS WITH SELECTING OF DONORS BY RED BLOOD CELLS ANTIGENS OF THE RHESUS SYSTEM
Authors: E. Butina, E. Poponina, A. Yovdiy, F. Sherstnev, G. Zaitseva, I. Paramonov
Journal: HemaSphere (2019)

Background: In April 2013, the Ministry of Health of the Russian Federation approved an order regulating transfusion therapy in hematology patients only taking into account the compatibility of the donor and recipient for the antigens C, c, E, e, C W . Aims: Assess the effectiveness of organizational measures for the prevention of alloimmunization to antigens of red blood cells in patients receiving intensive hemocomponent therapy. Methods: The results of immunohematological studies were analyzed in 3697 patients: 1961 patients were first admitted for treatment at a hematological clinic from 2007 to 2014; 1736 patients ‐ from 2015 to 2018. Non‐Hodgkin lymphoma was diagnosed in 767 patients, chronic myeloid leukemia in 220, chronic lymphocytic leukemia in 320, acute leukemia in 612, multiple myeloma in 398, myelodysplastic syndrome in 73, aplastic anemia ‐ in 147, other hematologic diseases ‐ in 1160. The studies were performed using equipment and reagents from BioRad (USA). Results: In 2007–2014, antibodies to antigens C, c, E, e, C W of the Rhesus system were detected in hematological patients with a frequency of 0.92%. Due to the phenotypic selection of donors, the level of alloimmunization decreased 2.6 times and amounted to 0.35% in 2015–2018 (χ 2 = 3,831; p = 0.05). The frequency of detection of antibodies to antigen C (0.25% and 0.06%, respectively) and to antigen E (0.46% vs 0.12%) decreased four times. The selection for the antigen was carried out in the clinic since 1998, therefore the immunization index for this antigen remained at the same level (0.10% vs 0.12%). The frequency of detection of antibodies to the C W antigen has not changed significantly (0.10% vs 0.06%). Alloantibodies to the antigen e were not detected for the entire observation period. Table. The frequency of detection of antibodies to antigens C, c, E, e, C W in hematological patients in the periods 2007–2014, 2015‐2018. Summary/Conclusion: Phenotypic selection of donors for antigens C, c, E of the Rhesus system is an effective method of preventing aloimmunization of patients receiving intensive hemocomponent therapy. The selection of red blood cells for antigens C W and e has no practical significance. image
AB1247 RISK FACTORS FOR ADVERSE CLINICAL OUTCOME IN SEPTIC SPONDYLODISCITIS
Authors: Aicha Ben Tekaya, Lobna Ben Ammar, Olfa Saidane, Rawdha Tekaya, Mohammed Ben Hammamia, Ines Mahmoud, Leila Abdelmoula
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Spondylodiscitis is defined as a serious infection of the intervertebral disc and/or adjacent vertebrae. It can lead to neurological sequelae and put life-threatening ones into play. <h3>Objectives:</h3> To describe the clinical features and outcomes of septic spondylodiscitis and to identify factors associated with an unfavourable clinical outcome. <h3>Methods:</h3> Retrospective study including 107 patients followed up in our department between 1999 and 2019. Clinical, radiological and microbiological data were collected. We divided patients into two groups: patients with unfavourable clinical outcome (defined as death, drug toxicity, neurological complication, sepsis or persistent pain) (group 1) and patients with a favourable one (Group 2). <h3>Results:</h3> We included 107 patients (49 women and 58 men), with a mean age of 55 years old [16 - 86]. The median delay of consultation was 3 months. Predisposing factors were found in 59 patients (55.1%). Inflammatory back pain was seen in 78.5% of cases. Neurologic deficiency was noticed in 16.82% of cases: motor deficit in 1.8% of cases, spinal cord compression in 1.8% of cases and Cauda equina s<i>yndrome in 2.8% of cases</i>. An inflammatory biological syndrome was found in 90.6% of cases. The lumbar spine was involved in 55%. The spondylitis was multifocal in 19.6% and multi-stage in 15.8% of cases. CT and Spinal MRI was performed respectively in 60% and 78.8% of cases and showed paravertebral abscess in 63.5%, epiduritis in 54.2%, intra-discal abscess in 4.67%, spinal cord compression 9.3%, and vertebral ostelysis in 8.4% of cases. The causative microorganism was mycobacterium tuberculosis in 59.8%, brucella in 20.56%, and pyogenic germs in 16.8% of cases. 34.5% of patients had an unfavourable clinical outcome: persistent pain was noticed in 18.7%,drug toxicity occurred in 13% of cases,neurological complication occurred in 10.2% of cases, sepsis occurred 3.7% of cases and 3.7% of patients were dead. In the group1 the frequency of diabetes, impairment of the general state and clinical evidence of neurological impairment at presentation was higher, but with no statistically significant difference. Similarly, the presence of paravertebral abscess, epiduritis or spinal cord compression was slightly more frequent, with no significant difference. There was no statically significant difference in the age (p=0.15), the localisation and the causative microorganism (p=0.68). <h3>Conclusion:</h3> Spondylodiscitis is a rare but serious condition that leads to significant long-term morbidity. In our study, unfavourable clinical outcomes was found in the presence of diabetes, neurological impairement at presentation and the presence of paravertebral abscess, epiduritis or spinal cord compression in MRI but with no statically significant difference. <h3>Disclosure of Interests:</h3> None declared
Reply to Mahler: Peak Inspiratory Flow Rate: An Emerging Biomarker in Chronic Obstructive Pulmonary Disease
Authors: Ann Chen Wu, Blanca E. Himes
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

We appreciate Mahler's correspondence related to our research statement (1), the goal of which was to identify knowledge gaps that future research studies can address to efficiently translate biomarkers into clinical practice.To reach this goal, we chose to focus on example biomarkers for select lung diseases rather than create a comprehensive list of all biomarkers for all pulmonary diseases.As stated in the article, "the biomarkers discussed in this research statement are not intended to be comprehensive."Thus, we did not state or intend to imply that fibrinogen is the "sole" biomarker in chronic obstructive pulmonary disease (COPD).We agree with Mahler that the peak inspiratory flow rate is a promising COPD biomarker, and encourage studies of this and other promising biomarkers for COPD and other lung diseases.
AB0964 DIAGNOSIS OF CROHN`S DISEASE IN PATIENTS WITH PRIMARY RHEUMATOLOGICAL MANIFESTATIONS
Authors: Evgeny Fedorov, Svetlana Salugina, Natalia Schigoleva, Maria Kaleda, Irina Nikishina, Elena Komelyagina, Olga Borodacheva, Anastasia Schigoleva
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Sometimes Crohn's disease (CD) manifests initially with rheumatological symptoms. Therefore, there's an important for a rheumatologist to recognize this pathology correctly and timely. <h3>Objectives</h3> To present cases of CD, referred to V.A. Nasonova Research Institute of Rheumatology. <h3>Methods</h3> Case series of 7 pts (5 boys, 2 girls) with initial rheumatological condition who developed CD. All pts were subjected to standard rheumatological examination. CD diagnosis was suggested by a rheumatologist and confirmed in gastroenterology hospital. <h3>Results</h3> Mean age at CD onset was 12,7±3,98 yrs, varying from 5 to 17 yrs. In 4 pts gastrointestinal (GIT) symptoms manifested simultaneously with rheumatological, in 2 pts GIT symptoms were delayed for 4 and 5 years. The time-interval from the onset of first symptoms until establishing CD diagnosis varied from 2 months till 6 years, averaging to 96± 38 months. The list of initial rheumatological diagnoses included the following entities: juvenile idiopathic arthritis (JIA) with oligoarticular onset – in 5 pts, and systemic onset JIA – in 2 pts. In all cases arthritis manifested initially as an oligo-involvement of a lower limb joints. High active sacroiliitis with deep bone oedema was detected by MRI in 5 pts. Fever was present in 5 pts, uveitis – in 1, cutaneous psoriasis – in 1. Other documented symptoms included: weight loss (3), hepatosplenomegaly (1), lymphadenopathy (1), aphthouse stomatitis (1), nodular erythema (1), erythematous rash (1). HLA B27-antigen positivity was established in 3 pts out of 5 examined. All pts had significant increase in CRP and ESR levels and WBC counts; (additionally 3 examined for calprotectin cases demonstrated significant increase of its' concentration (&gt;1000 µg/g). <h3>Conclusion</h3> IBD, including CD, should not be missed and ruled out in all pts with oligoarticular and systemic JIA onset. Fecal calprotectin should be checked in suspected CD cases among individuals with rheumatologic symptoms. Special attention should be given to cases manifesting during puberty, accompanied by weight loss, fever, GIT symptoms, increased levels of acute phase inflammatory markers. MRI stir lesion may be as suspected of IBD especial CD. <h3>Disclosure of Interests</h3> None declared
SP0209 EULAR RECOMMENDATIONS FOR REPORTING IN MSK ULTRASOUND STUDIES
Authors: Maria-Antonietta d”Agostino
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Ultrasound is now considered as an established imaging modality for the management of rheumatic and musculoskeletal diseases (RMDs). However, the reporting of ultrasound information in clinical studies is often inadequate and/or incomplete which hampers the assessment of the generalizability and applicability of their results. Objectives: to develop European League Against Rheumatism (EULAR) recommendations for the reporting of ultrasound studies in RMDs with the ultimate goal to produce a "reporting checklist" containing a minimal list of items that should be checked when a study using ultrasound is submitted for publication. <h3>Methods:</h3> Following the standardised operating procedures for EULAR-endorsed recommendations, a task force has been created, including ultrasound experts, methodologists, patients and health professionals. After a first face-to-face meeting, preliminary recommendations were formulated together with research questions to drive the literature reviews. Based on the results of the literature reviews and on the results of several DELPHI rounds with the participation of external experts, these preliminary recommendations were then refined during a second face-to-face meeting in November 2018. <h3>Results:</h3> The current checklist comprises 21 items (19 mandatory and two optional) divided into 13 sections. For helping the interpretation of some specific terms, a glossary has also been created, including 12 definitions. The checklist is currently evaluated by external experts to assess its comprehensiveness. Finally, all the members of the task force will be asked to give their level of agreement with each of the items. Conclusion: this checklist will help to improve quality and completeness in reporting of ultrasound studies in RMDs. <h3>Disclosure of Interests:</h3> None declared
Helping late career and retired doctors contribute to the health service
Authors: Mona Aquilina
Journal: BMJ (2019)

I agree with Gerada that the skills of older doctors should be used in the health service.1 She did not mention doctors who have planned to retire from clinical practice at around 60, the current “normal” retirement age, and do so not through burnout or revalidation issues but as part of their life plan. They …
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Authors: Aude G. Chapuis, Daniel N. Egan, Merav Bar, Thomas M. Schmitt, Megan S. McAfee, Kelly G. Paulson, Valentin Voillet, Raphael Gottardo, Gunnar B. Ragnarsson, Marie Bleakley, Cecilia C. Yeung, Petri Muhlhauser, Hieu N. Nguyen, Lara A. Kropp, Luca Castelli, Felecia Wagener, Daniel Hunter, Marcus Lindberg, Kristen Cohen, Aaron Seese, M. Juliana McElrath, Natalie Duerkopp, Ted A. Gooley, Philip D. Greenberg
Journal: Nature Medicine (2019)